Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

AYTU - Aytu BioPharma, Inc. Financial Statements | Finranks

Home

/

AYTU

A

Aytu BioPharma, Inc. (AYTU)

NCM – Real Time Price. Currency in USD

2.38

-0.02 (-0.65%)

Market open: Aug 12, 2026, 2:42 PM EDT

2.40

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Total Assets

Total Liabilities

Stockholders Equity

Total Debt

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

66M

65M

107M

97M

Cost of goods sold

-24M

-20M

-46M

-50M

Gross Profit

42M

45M

62M

46M

Operating expenses (excl. COGS)

-40M

-45M

-74M

-85M

Operating Income

3M

565K

-12M

-38M

Non-operating income, total

-16M

-11M

-5M

-71M

Pretax income

-14M

-10M

-17M

-109M

Equity in earnings

0

0

0

0

Taxes

-437K

-2M

0

110K

Non-controlling/minority interest

0

0

0

0

After tax other income/expense

0

0

0

0

Net income before discontinued operations

-14M

-13M

-17M

-109M

Discontinued operations

620K

-3M

0

0

Net income

-14M

-16M

-17M

-109M

Dilution adjustment

0

0

0

0

Preferred dividends

0

0

0

0

Name

2025

2024

2023

2022

Total assets

124M+4.7%

119M-13.8%

138M+0.2%

138M

Total current assets

79M

62M

73M

60M

Total non-current assets

45M

57M

65M

78M

Total liabilities

105M+15.7%

91M-7.5%

98M+5.5%

93M

Total current liabilities

63M

62M

69M

64M

Total non-current liabilities

42M

29M

29M

29M

Total equity

19M

28M

39M

44M

Total liabilities & shareholders' equities

124M

119M

138M

138M

Total debt

23M+39.7%

16M-46.0%

30M-16.3%

36M

Name

2025

2024

2023

2022

Cash from operating activities

-2M

-1M

-5M

-29M

Cash from investing activities

-3M

-329K

-117K

-3M

Cash from financing activities

15M

-1M

9M

2M

Free cash flow

-2M-26.1%

-2M+67.1%

-5M+81.9%

-29M